Welcome to our dedicated page for Crinetics Pharmaceuticals news (Ticker: CRNX), a resource for investors and traders seeking the latest updates and insights on Crinetics Pharmaceuticals stock.
Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) generates frequent news flow around its efforts to develop and commercialize therapies for endocrine diseases and endocrine-related tumors. Company announcements highlight progress across its GPCR-targeted small-molecule portfolio, including regulatory milestones, clinical trial updates, capital markets activity, and corporate developments.
News coverage often focuses on PALSONIFY™ (paltusotine), Crinetics’ once-daily, oral somatostatin receptor type 2 agonist. Updates have included U.S. FDA approval for adults with acromegaly who had an inadequate response to surgery and/or for whom surgery is not an option, early launch metrics, and the design and enrollment status of the pivotal Phase 3 CAREFNDR trial in carcinoid syndrome associated with neuroendocrine tumors.
Investors and observers can also follow regular announcements on atumelnant, the company’s investigational ACTH receptor antagonist in late-stage development for classic congenital adrenal hyperplasia (CAH) and ACTH-dependent Cushing’s syndrome. Press releases describe Phase 2 results, the CALM-CAH Phase 3 trial design, biomarker changes such as reductions in androstenedione, and safety observations from both core studies and open-label extensions.
Additional news items cover the advancement of CRN09682, a nonpeptide drug conjugate targeting SST2-expressing tumors, including first-patient dosing in the Phase 1/2 BRAVESST2 trial and details of the trial’s dose-escalation and expansion phases. Crinetics also reports on preclinical programs like CRN12755 and CRN10329 through R&D Day presentations and conference abstracts.
Beyond R&D, Crinetics issues releases on public offerings of common stock, inducement equity grants under its 2021 Employment Inducement Incentive Award Plan, participation in major healthcare conferences, and executive transitions disclosed via Form 8-K. For users tracking CRNX, this news page provides a centralized view of the company’s clinical, regulatory, financial, and corporate announcements over time.
Crinetics Pharmaceuticals (Nasdaq: CRNX) will report third quarter 2025 financial results on Thursday, November 6, 2025 after the market closes.
Management will host a conference call and webcast at 4:30 p.m. ET to discuss results and provide a business update. Dial-in numbers are provided for domestic and international callers and the access code 166837 applies. A live webcast will be available via the company's Events/Investor Relations pages and will be archived for later viewing. Participants are recommended to connect at least 15 minutes before the scheduled start to ensure a timely connection.
Crinetics Pharmaceuticals (Nasdaq: CRNX) has received FDA approval for PALSONIFY™ (paltusotine), marking a significant breakthrough as the first once-daily, oral treatment for adults with acromegaly. The approval is based on successful results from two Phase 3 trials, PATHFNDR-1 and PATHFNDR-2, where the drug demonstrated rapid onset, reliable biochemical control, and sustained efficacy.
The drug is specifically approved for adults with acromegaly who had inadequate response to surgery or for whom surgery isn't an option. Clinical trials showed significant symptom reduction and strong safety profile, with 91% and 97% of patients from respective trials enrolling in the open-label extension. PALSONIFY will be available in the U.S. in early October 2025, supported by CrinetiCARE®, a comprehensive patient support program.
Crinetics Pharmaceuticals (Nasdaq: CRNX) has announced new equity grants under its 2021 Employment Inducement Incentive Award Plan. The company granted 62,475 non-qualified stock options and 43,800 restricted stock units (RSUs) to 20 new non-executive employees on September 10, 2025.
The stock options have an exercise price of $35.00 per share, matching CRNX's closing price on the grant date. Both options and RSUs will vest over four years, with options vesting 25% after one year and monthly thereafter, while RSUs will vest in equal annual installments.
Crinetics Pharmaceuticals (Nasdaq: CRNX) announced that its drug candidate atumelnant received FDA Orphan Drug Designation for treating congenital adrenal hyperplasia (CAH). Atumelnant is the first and only small molecule ACTH receptor antagonist in clinical development.
The company reported positive Phase 2 results in January 2025, showing up to 80% mean reduction in androstenedione and improvements in clinical symptoms. Crinetics plans to initiate Phase 3 CALM-CAH study in adults and Phase 2/3 BALANCE-CAH study in pediatrics in H2 2025.
The Orphan Drug Designation provides benefits including potential financial incentives and seven years of market exclusivity upon approval for treating this rare disease affecting fewer than 200,000 people in the U.S.
Crinetics Pharmaceuticals (Nasdaq: CRNX) announced equity inducement grants for 27 new non-executive employees. The compensation package includes 75,850 non-qualified stock options with an exercise price of $26.85 per share and 53,400 restricted stock units (RSUs).
The stock options will vest over four years, with 25% vesting after one year and the remainder vesting monthly over 36 months. The RSUs will vest in equal annual installments over four years. These grants were made under the company's 2021 Employment Inducement Incentive Award Plan, complying with Nasdaq Listing Rule 5635(c)(4).
Crinetics Pharmaceuticals (Nasdaq: CRNX) reported Q2 2025 financial results and significant progress across its endocrine disease pipeline. The company's lead candidate PALSONIFY™ (paltusotine) has a PDUFA date of September 25, 2025, for acromegaly treatment. Q2 financial highlights include $1.2B in cash providing runway into 2029, revenues of $1.0M, and a net loss of $115.6M.
The company is advancing multiple clinical programs, including atumelnant's global development with the BALANCE-CAH Phase 2/3 pediatric study planned for 2025. The EMA validated paltusotine's MAA for acromegaly with a potential decision in H1 2026. R&D expenses increased to $80.3M, while SG&A expenses rose to $49.8M, reflecting expansion of clinical programs and commercial preparation efforts.
Crinetics Pharmaceuticals (Nasdaq: CRNX) announced new long-term data for PALSONIFY™ (paltusotine), their investigational once-daily oral treatment for acromegaly, to be presented at ENDO 2025. The data comes from open-label extensions of two Phase 3 trials: PATHFNDR-1 and PATHFNDR-2.
Key findings through Week 96 show that PALSONIFY maintained stable IGF-1 levels in patients who switched from injectable treatments, with mean IGF-1 levels of 0.81 times the upper limit of normal. In PATHFNDR-2, patients showed sustained IGF-1 reductions, with a mean change of -0.81 × ULN at Week 84. The drug demonstrated durable biochemical control, reduced symptom burden, and was generally well-tolerated across both studies.
Crinetics Pharmaceuticals (NASDAQ:CRNX) has scheduled its second quarter 2025 financial results announcement for Thursday, August 7, 2025, after market close. The company will host a conference call at 4:30 p.m. ET featuring management discussion of financial results and a business update.
Investors can participate via phone using domestic (1-833-470-1428) or international (1-404-975-4839) dial-in numbers with access code 899803, or through a live webcast available on the company's website. Participants are advised to connect 15 minutes before the call, and a webcast replay will be available in the Investor Relations section of www.crinetics.com.
Crinetics Pharmaceuticals (Nasdaq: CRNX) announced new equity grants under its 2021 Employment Inducement Incentive Award Plan. The company granted 102,350 non-qualified stock options and 77,875 restricted stock units (RSUs) to 46 new non-executive employees.
The stock options have an exercise price of $31.99 per share, equal to CRNX's closing price on July 10, 2025. Both options and RSUs will vest over four years, with options having a 25% first-year cliff and monthly installments thereafter, while RSUs vest in equal annual installments.
Crinetics Pharmaceuticals (Nasdaq: CRNX) announced it will present eight abstracts from its clinical development programs at ENDO 2025, taking place July 12-15, 2025, in San Francisco. The presentations will showcase data from multiple drug candidates across their endocrinology pipeline.
Key highlights include long-term efficacy and safety data for PALSONIFY™ (paltusotine) in acromegaly, featuring four abstracts demonstrating consistent biochemical and symptom control in patients. The company will present Phase 2 trial results for atumelnant in congenital adrenal hyperplasia (CAH) through three abstracts, including data on adrenal volume reduction and androgens reduction.
Additionally, Crinetics will present new data from its early-stage pipeline, including CRN12755 for Graves' hyperthyroidism and orbitopathy. The company will also host two sponsored science and innovation theaters focusing on acromegaly management.